Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

primary analysis comparing the 900-mcg albinterferon alfa-2b treatment group to the peginterferon alfa-2a treatment group.

  • Based on an ITT analysis of results for the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, 47.3% (208/440) of patients in this treatment group achieved SVR, vs. 51.0% (225/441) in the peginterferon alfa-2a treatment group, which statistically demonstrated non-inferiority (95% CI -9.4%, 3.2%, p=0.0029, adjusted for baseline stratification factors).
  • The incidence of serious and/or severe adverse events was 28.3% (124/440) in the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, vs. 23.1% (102/441) in the peginterferon alfa-2a treatment group.
  • The incidence of serious and/or severe pulmonary adverse events included the following: serious and/or severe pulmonary infections were 3.2% (14/440) for 1200-mcg albinterferon alfa-2b, vs. 1.1% (5/441) for peginterferon alfa-2a; and serious and/or severe respiratory, thoracic or mediastinal disorders were 3.0% (13/440) for 1200-mcg albinterferon alfa-2b, vs. 0.5% (2/441) for peginterferon alfa-2a.
  • Overall, adverse events observed were those typically expected with interferon therapy. The incidence of discontinuations due to adverse events was 10.0% (44/440) in the treatment group originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks, vs. 4.1% (18/441) in the peginterferon alfa-2a treatment group.

Additional Safety Data of Interest from the Phase 3 Clinical Trials of Albinterferon Alfa-2b Versus Peginterferon Alfa-2a

HGS has conducted two randomized active-controlled Phase 3 clinical trials of albinterferon alfa-2b versus peginterferon alfa-2a - ACHIEVE 1 in genotype 1 chronic hepatitis C, and ACHIEVE 2/3 in genotypes 2 and 3 chronic hepatitis C.
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... , , SAN DIEGO, Aug. 27 ... Company has begun a clinical trial intended to secure U.S. regulatory approval ... determine the need for a repeat prostate biopsy. , ... studies and our European commercial experience, we believe that our PROGENSA PCA3 ...
... , , , ... an 82-year old New Orleans resident with severe aortic stenosis successfully had ... as angioplasty, a far cry from the traditional open heart procedure. Patients ... now have a potential new research option available regionally only through The ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 2Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 3Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 4Ochsner Replaces Heart Valve Without Open Heart Surgery 2
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually consist of ... coating, opacity, and coloring. These are water and oil ... substances such as paper, paints, plastics, and concrete. Binders ... impart color to the substance. Some examples of pigments ... , The coloring action of pigments is due to ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... a 47-year-old man who had worked for a Hindustan Lever ... who had also been exposed to toxic mercury, to the ... than 500 protestors, who said he had been slowly poisoned ... an autopsy to assess the possibility of mercury-induced damage. ...
... new study examined the connection between Baltimore City’s needle ... ,Individuals who enter treatment programs for drug addiction were ... Baltimore City needle exchange programs. ,The ... of Public Health highlights the need for treatment facilities ...
... always the result of a subtle marriage between a ... an appropriate excipient// (a neutral substance in which the ... absorbed by the body). Thus the necessary tablet, capsule ... biodegradable materials were used instead of these neutral excipients? ...
... multiple positive social outcomes,// research conducted in rural ... of the Journal of Acquired Immune Deficiency Syndromes ... appear to lead to stigmatisation or an increase ... increase in the incidence of domestic violence against ...
... transition service has been instituted by the NHS trust to ... ,‘Minding the Gap’, a document enabled by ... regular service for 16- to 18-year-olds, in Durham and Darlington. ... out to the teenagers suffering health problems across six primary ...
... Complementary //and Alternative Medicine (NCCAM) at the National Institutes ... better, especially about alternative therapies they are trying out ... ,This is the outcome of a survey conducted ... 1600 patients, and their doctors. ,It ...
Cached Medicine News:Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2Health News:Drug Treatment Seekers Likely to Use Needle Exchange 2Health News:New Generation - Medicinal Products 2Health News:New Generation - Medicinal Products 3Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 2Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 3Health News:Elderly Patients Usually Keep Mum About Use of Alternative Medicine , Reveals Survey 2
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: